AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X

Find Drugs in Development News & Deals for Ranibizumab

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

CIMERLI (Ranibizumab) is the first and only interchangeable biosimilar with an exclusivity for 12 months after market launch that is indicated for the treatment of all five Lucentis® indications and, as such, is a new medical option for patients with serious retinal diseases.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2022

Details:

CIMERLI™ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI™. Hypersensitivity reactions may manifest as severe intraocular inflammation


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2022

Details:

Under the exclusive agreement, MS Pharma will be responsible for the registration and commercialization of FYB201/CHS-201 (Ranibizumab), in the Middle East and North African countries. MS Pharma will start the registration procedures in MENA immediately.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: CHS-201

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: MS Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 14, 2021

Details:

CHS-201 (ranibizumab), trade name Lucentis® among others is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration a common form of age-related vision loss.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: CHS-201

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 06, 2021

Details:

Ranivisio (ranibizumab) is a VEGF-A inhibitor, which is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Ranivisio

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 11, 2023

Details:

The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A. Ranivisio is a biosimilar medicinal product.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Ranivisio

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2022

Details:

Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Sandoz B2B

Deal Size: $170.0 million Upfront Cash: $170.0 million

Deal Type: Divestment March 04, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

The newly formed Eyconis has exclusive rights to develop and commercialize TransCon RBZ (ranibizumab) ophthalmology products globally, which are used for the treatment of wet age-related macular degeneration (AMD).


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: TransCon RBZ

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Ascendis Pharma

Deal Size: $248.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 29, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Sandoz B2B

Deal Size: $170.0 million Upfront Cash: $170.0 million

Deal Type: Divestment January 22, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The funding aims to support the OPT-302 (sozinibercept) in combination with ranibizumab, which is the first-in-class VEGF-C/D ‘trap’ in clinical development for Wet age-related macular degeneration.


Lead Product(s): Sozinibercept,Ranibizumab

Therapeutic Area: Ophthalmology Product Name: OPT-302

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Carlyle Group

Deal Size: $170.0 million Upfront Cash: Undisclosed

Deal Type: Financing December 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company intends to use the net proceeds for advancing the Phase 3 clinical trials ShORe and COAST for OPT-302 (sozinibercept), a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D, for the treatment of wet AMD.


Lead Product(s): Sozinibercept,Ranibizumab

Therapeutic Area: Ophthalmology Product Name: OPT-302

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $57.6 million Upfront Cash: Undisclosed

Deal Type: Financing August 28, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OPT-302 (sozinibercept) is a novel recombinant trap fusion protein targeting inhibition of vascular endothelial growth factors C and D (VEGF-C and VEGF-C), two ligand mediators of angiogenesis and vascular leakage involved in retinal vascular diseases.


Lead Product(s): Sozinibercept,Ranibizumab

Therapeutic Area: Ophthalmology Product Name: OPT-302

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OPT-302, a VEGF-C/D inhibitor being investigated for neovascular age-related macular degeneration. It binds to and neutralizes the activity of VEGF-C and VEGF-D by preventing ligand binding to the endogenous receptors VEGFR-2 and VEGFR-3.


Lead Product(s): OPT-302,Ranibizumab

Therapeutic Area: Ophthalmology Product Name: OPT-302

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Ximluci

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Xbrane Biopharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CIMERLI (ranibizumab-eqrn) is indicated for patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ranivisio (ranibizumab) is indicated for the treatment of neovascular (wet) age-related macular degeneration, treatment of visual impairment due to diabetic macular oedema or choroidal neovascularization, proliferative diabetic retinopathy, as well as visual impairment.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Ranivisio

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Bioeq IP AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cimerli (ranibizumab-eqrn), a VEGF inhibitor, is indicated for treatment of patients with neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Brand Institute

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The COLUMBUS-AMD study, published in highly-regarded medical journal Ophthalmology, was the head-to-head study where CIMERLI (ranibizumab) met its primary endpoint of change from baseline in best corrected visual acuity (BCVA) at week 8 as compared to reference ranibizumab.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Cimerli

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Polpharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

BYOOVIZ™ (ranibizumab-nuna), priced 40% lower than LUCENTIS®, provides an equally effective and more affordable treatment option to patients suffering from retinal disorders.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Byooviz

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Samsung Bioepis

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MHRA granted a licence for Ongavia® (ranibizumab), a biosimilar to Lucentis®*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic macular oedema and proliferative diabetic retinopathy.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Product Name: Ongavia

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Bioeq IP AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 17, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Of the 366 participants dosed for OPT-302, 66 (18%) were identified as having PCV lesions at baseline based on multimodal imaging analysis of color fundus photography, fluorescein angiography and SD-OCT.


Lead Product(s): OPT-302,Ranibizumab

Therapeutic Area: Ophthalmology Product Name: OPT-302

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content